The standard of care with regard to adjuvant chemotherapy of lung cancer has changed remarkably over the past 3 years. Until the initial report of the International Adjuvant Lung Trial in 2003, there was no real evidence from any individual randomized clinical trial (RCT) that adjuvant chemotherapy improves survival in resectable non-small-cell lung cancer. However, five RCTs that have now been reported indicate that adjuvant chemotherapy is effective, at least in certain subgroups of resectable patients. Moreover, numerous meta-analyses have also reported a positive effect from adjuvant treatment. Nonetheless, because of methodologic issues and conflicting results, the question of who should be treated and what constitutes optimal adjuvant therapy remains controversial. This article reviews the recent randomized trials that have contributed to a change in the state of the art, as well as some of the methodologic problems that may have confounded their proper interpretation. It also considers newer approaches to adjuvant therapy, with a particular focus on strategies that incorporate our growing knowledge of molecular medicine and predictive factors to the field of adjuvant chemotherapy of lung cancer.
Lung cancer remains the most frequent cause of cancer death both in the United States and worldwide.[1,2] The American Cancer Society (ACS) estimates that lung cancer is the third most common cancer in the US, ranking behind prostate cancer and breast cancer (Table 1). However, in terms of cancer mortality, it is in a league of its own.
Indeed, the ACS estimates that lung cancer will be responsible for 162,460 cancer deaths in the US in 2006. By way of comparison, an estimated 156,250 deaths were expected from colorectal cancer, breast cancer, pancreatic cancer, and prostate cancer combined. These diseases represent the second through fifth leading causes of cancer mortality, respectively (Table 1). It is estimated that lung cancer will be responsible for 28.8% of all cancer deaths in the US in 2006, despite the fact that it represents only 12.5% of all new cancers. Overall, 5-year survival in the US is currently estimated to be approximately 15%.
On a worldwide basis, lung cancer is both the most common cancer and most common cause of cancer mortality. In the year 2002, there were an estimated 1,350,000 new cases of lung cancer, and an estimated 1,179,000 lung cancer deaths. Globally, lung cancer represents 12.4% of all new cancers, and 17.6% of all cancer deaths. Overall, 5-year survival is estimated to be 10% in Europe and 9% in developing countries.
Among patients with early-stage non-small-cell lung cancer (NSCLC), the most powerful predictor of long-term survival is the ability to achieve complete surgical resection. Nonetheless, patients remain at substantial risk for recurrence and death despite an apparent complete surgical excision. For example, data reported by Mountain in 1986 that were used to establish the International Staging System for lung cancer included 5-year survival rates of 64% and 45% for patients with pathologic stage I or II disease, respectively (Table 2). High recurrence rates among those with resected lung cancer underscore the potential role of adjuvant chemotherapy in this setting.
While a considerable risk of recurrence and death following resection has long provided a powerful rationale for adjuvant treatment, research in the area of adjuvant chemotherapy has never received the same priority in NSCLC as it has in other common cancers, particularly breast and colorectal cancer. Nonetheless, several influential randomized clinical trials on adjuvant chemotherapy in lung cancer and an important meta-analysis of trials did appear in the literature prior to 2003, when the first positive report from a large randomized trial was published, helping to change the standard of care.
I will briefly review the most influential of these older randomized trials along with the meta-analysis. Subsequently, I will address recent randomized trials that have led to a change in clinical practice in resectable NSCLC. In the discussion section, I will attempt to define the current state of the art in adjuvant therapy and to articulate major unanswered questions. Finally, I will consider newer approaches to adjuvant therapy in lung cancer.
Randomized Trials and Meta-Analysis Published Prior to 2003
Three cisplatin-based adjuvant randomized trials sponsored by the Lung Cancer Study Group (LCSG) are among the best known older studies in the area of adjuvant chemotherapy of lung cancer. Each trial utilized an adjuvant chemotherapy regimen consisting of the CAP (cyclohphosphamide, doxorubicin [Adriamycin], and cisplatin [Platinol]) regimen in various stages of NSCLC.
LCSG-772 randomized 141 patients with resected stage II or III adenocarcinoma or large-cell carcinoma of the lung to six cycles of CAP chemotherapy or to a control group that received no chemotherapy. (It should be noted that control participants did receive an immunotherapy regimen, consisting of intrapleural bacillus Calmette-Guérin (BCG) and levamisole, for which there is no other evidence for efficacy.) While early results indicated a 15% survival advantage at 1 year (77% vs 62%), continued follow-up failed to reveal any significant long-term survival advantage.
LCSG-791 randomized 172 patients with incompletely resected NSCLC, as defined either by the presence of tumor in the highest resected mediastinal node, or by a positive margin. Patients were randomized to either adjuvant CAP chemotherapy with postoperative radiation (40 Gy) or to postoperative radiation therapy alone. This study also showed significantly better survival at 1 year in the CAP arm (68% vs 54%), although with longer follow-up the significant survival advantage disappeared.
LCSG-801 randomized 283 patients with T2, N0 or T1, N1 NSCLC to either four cycles of CAP or no adjuvant therapy. Overall, 85% of participants had T2, N0 and 15% had T1, N1 tumors. Five-year survival was 55% in both groups. While compliance and delivery of the intended therapy was problematic, the results of this trial were clearly negative.
In contrast, however, a smaller study conducted at Helsinki University Central Hospital in Finland, with a very similar design to LCSG-801, was the only individual randomized trial to report a significant survival advantage. In this trial, 110 patients with T1-3, N0 NSCLC were randomized to surgery followed by six cycles of CAP chemotherapy or to surgery alone. Stage distribution included 31% with T1, N0 disease, 62% with T2, N0 disease, and 7% with T3, N0 NSCLC.
The investigators found a statistically significant 5-year survival advantage favoring the adjuvant chemotherapy arm (67% vs 56%; P = .050). However, problems with randomization appear to have confounded interpretation of this trial: Those randomized to surgery alone included almost twice as many patients who required pneumonectomy as was true in the adjuvant chemotherapy arm (39% vs 20%; P = .038). As would be expected, pneumonectomy patients had a significantly worse survival than those requiring lobectomy (P = .002).
Two randomized trials conducted in predominantly stage II and III NSCLC failed to demonstrate a survival benefit for adjuvant chemotherapy and radiation compared to adjuvant radiation alone. In a French trial conducted by the Groupe D'etude et de Traitement des Cancer Bronchiques (GETCB), 267 patients were randomized to either adjuvant chemotherapy with COPAC (cyclophosphamide, vincristine [Oncovin], cisplatin, doxorubicin, lomustine [CeeNU]), followed by 60 Gy of postoperative radiation therapy (PORT) over 6 weeks or to PORT alone. Stage distribution included 70% with stage III, 26% with stage II, and 3% with stage I disease. With a minimum follow-up of 6 years, survival was similar in the two groups (P = .68).
Finally, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized trial comparing adjuvant chemoradiation vs PORT alone in completely resected stage II or IIIA NSCLC. In this study, 488 patients were randomized to receive four cycles of adjuvant chemotherapy with cisplatin and etoposide and concurrent radiation (50.4 Gy) or to a similar PORT regimen. Survival was virtually identical within the two groups (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.74-1.18).
While none of these or other older randomized trials demonstrated a clear and unequivocal survival advantage associated with randomization to adjuvant chemotherapy, a meta-analysis of chemotherapy in NSCLC published in 1995 did suggest a survival benefit for those randomized to cisplatin-based adjuvant chemotherapy regimens. Eight trials utilizing a cisplatin-based adjuvant chemotherapy regimen showed an overall 13% proportional reduction in the risk of death among those receiving adjuvant chemotherapy. This translated into an absolute 5% improvement in the probability of long-term survival among those receiving adjuvant treatment. However, the difference favoring cisplatin-based adjuvant chemotherapy was not statistically significant (HR = 0.87; 95% CI = 0.74-1.02; P = .08).
Nonetheless, the 5% survival advantage observed in the 1995 meta-analysis with cisplatin-based chemotherapy provided an incentive for conducting additional randomized trials in this area. Several of these studies have now been reported and have dramatically changed the practice of medicine as it relates to adjuvant chemotherapy for NSCLC. On the other hand, numerous important questions remain. The next several sections review key recent trials that have begun to answer these questions.
The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Parkin D, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics-2006. CA Cancer J Clin 56:106-130, 2006.
3. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986.
4. Strauss GM: Adjuvant chemotherapy of lung cancer: Methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 19:263-281, 2005.
5. Holmes EC, Gail M, for the Lung Cancer Study Group: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710-715, 1986.
6. Lad T, Rubinstein L, Sadeghi A, for the Lung Cancer Study Group: The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 6:9-17, 1988.
7. Feld R, Rubinstein L, Thomas PA: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. J Natl Cancer Inst 85:299-306, 1993.
8. Niranen A, Niitamo-Korhonen S, Kouri M, et al: Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study. J Clin Oncol 10:1927-1932, 1992.
9. Dautzenberg B, Chastang C, Arriagada R, et al: Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non-small cell lung carcinoma. Cancer 76:779-786, 1995.
10. Keller SM, Adak S, Wagner H, et al: A randomized trial of postoperative adjuvant therapy in patient with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med 343:1217-1222, 2000.
11. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-911, 1995.
12. Le Chevalier T, for the IALT Investigators: Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy versus no chemotherapy in 1867 patients with resected non-small cell lung cancer (abstract 6). Proc Am Soc Clin Oncol 22:2, 2003.
13. Arriagada R, Bergman B, Dunant A, et al, for the International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: N Engl J Med 350:351-360, 2004.
14. Peto R, Collins R, Gray R: Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 48:23-40, 1995.
15. Yusuf S, Collins R, Peto R: Why do we need large, simple randomized trials? Statistics in Medicine 3:409-420, 1984.
16. Collins R, Peto R, Gray R, et al: Large scale randomized evidence: Trials and overviews, in Warrel D, Cox T, Firth J, et al (eds): Oxford Textbook of Medicine, pp 24-36. Oxford, Oxford University Press, 2003.
17. Greenland S, Rothman KJ: Introduction to stratified analysis, in Rothman KJ, Greenland S (eds): Modern Epidemiology, pp 253-279. Philadelphia, Lippincott-Raven, 1998.
18. Greenland S, Rothman KJ: Concepts of interaction, in Rothman KJ, Greenland S (eds): Modern Epidemiology, pp 329-342. Philadelphia, Lippincott-Raven, 1998.
19. Scagliotti G, Fossati R, Torri V, et al: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1453-1461, 2003.
20. Waller D, Fairlamb D, Gower N, et al: The Big Lung Trial: Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting (abstract 2543). Proc Am Soc Clin Oncol 22:632, 2003.
21. Waller D, Peake M, Stephens R, et al: Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182, 2004.
22. Harrington DP: The randomized clinical trial, in Raftery AE, Tanner MA, Wells MT (eds): Statistics in the 21st Century, pp 67-74. Alexandria, Va, American Statistical Association-Chapman & Hall/CRC, 2002.
23. Rothwell P: Can overall results of clinical trials be applied to all patients? Lancet 345:1616-1619, 1995.
24. Lau J, Ioannidis J, Schmid C: Summing up evidence: One answer is not always enough. Lancet 351:123-127, 1998.
25. Diasio R: Adjuvant chemotherapy for adenocarcinoma of the lung-is the standard of care ready for change? N Engl J Med 350:1777-1779, 2004.
26. Hamada C, Tanaka F, Ohta M, et al: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006, 2005.
27. Wada H, Hitami S, Teramatsu, T, West Japan Study Group for Lung Cancer Surgery: Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 14:1048-1054, 1996.
28. Endo C, Saito Y, Iwanami H, et al: A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40:181, 2003.
29. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004.
30. Nakagawa M, Tanaka F, Tsubota N, et al: A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: The West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol 16:75-80, 2005.
31. Winton T, Livingston R, Johnson D, et al: A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer: Intergroup JBR 10 (abstract 7018). J Clin Oncol 22(14S):621s, 200.
32. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
33. Peppe C, Hasan B, Winton T, et al: Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 (abstract 7009). J Clin Oncol 24(18S):366s, 2006.
34. Winton T, Ding K, Seymour L: Treatment of resected non-small cell lung cancer (letter). N Engl J Med 353:1523-1524, 2005.
35. Douillard J-Y, Rosell R, De Lena M, et al: ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) NSCLC patients: Final results after 70 months of follow-up, on behalf of Adjuvant Navelbine International Trialist Association (abstract 7013). J Clin Oncol 23(16S):624s, 2005.
36. Douillard J-Y, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomized controlled trial. Lancet Oncology 7:719-727, 2006.
37. Alam N, Shepherd F, Winton T, et al: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 47:385-394, 2005.
38. Strauss GM, Herndon JE, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7019). J Clin Oncol 22(14S):621a, 2004.
39. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7007). J Clin Oncol 24(18S):365s, 2006.
40. Sedrakyan A, van Der Meulen J, O'Byrne K, et al: Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 128:414-419, 2004.
41. Hotta K, Matsuo K, Ueoka H, et al: Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22:3860-3867, 2004.
42. Alam N, Darling G, Shepherd FA, et al: Postoperative chemotherapy in nonsmall cell lung cancer: A systematic review. Ann Thorac Surg 81:1926-1936, 2006.
43. Berghmans T, Paesmans M, Meert AP, et al: Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 49:13-23, 2005.
44. Pignon J, Tribodet H, Scagliotti J, et al: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients (abstract 7008). J Clin Oncol 24(18S):366s, 2006.
45. Douillard JY, Tribodet H, His P, et al: Lung Adjuvant Cisplatin Evaluation (LACE vinorelbine Project): Pooled analysis of adjuvant vinorelbine-cisplatin trials for completely resected non-small cell lung cancer (NSCLC) (abstract 7100). Ann Oncol 17(suppl 9):213, 2006.
46. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. Lancet Oncology 2:475-482, 2001.
47. Rothwell PM: Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 365:176-186, 2005.
48. Thompson SG, Higgins JP: Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet 365:341-346, 2005.
49. Lagakos SW: The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354:1667-1669, 2006.
50. Feinstein AR: Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48:71-79, 1995.
51. Borzak S, Ridker P: Discordance between meta-analyses and large-scale randomized, controlled trials. Ann Intern Med 123:873-877, 1995.
52. Petitti DB: Statistical methods in meta-analysis, in Meta-Analysis, Decision Analysis, and Cost Effectiveness, pp 94-118. Oxford, Oxford University Press, 2000.
53. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986.
54. Romond E, Perez E, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005.
55. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
56. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004.
57. Fan C, Oh D, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:360-369, 2006.
58. O'Shaughnessy J: Molecular signatures predict outcomes of breast cancer. N Engl J Med 355:615-617, 2006.
59. Paik S: Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 18:59-63, 2006.
60. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006.
61. Olaussen K, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006.
62. Burdett S, Stewart L, for the PORT Meta-analysis Group: Postoperative radiotherapy in non-small-cell lung cancer: Update of an individual patient data meta-analysis. Lung Cancer 47:81-83, 2005.
63. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:257-263, 1998.
64. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev CD002142, 2003.
65. Lally BE, Zelterman D, Colasanto JM, et al: Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24:2998-3006, 2006.
66. Betticher D: Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. Lung Cancer 50(suppl 2):S9-S16, 2005.
67. Pisters K, Ginsberg R, Giroux D, et al: Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer: Long-term follow-up of a phase II trial (abstract 2544). Proc Am Soc Clin Oncol 22:633a, 2003.
68. Pisters K, Vallieres E, Bunn P, et al: S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results (abstract 7012). J Clin Oncol 23(16S):633, 2005.
69. Rosell R, Felip E, Maestre J, et al: The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 34(suppl 3):S63-S74, 2001.
70. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004.
71. Ardizzoni A, Tiseo M, Boni L, et al: CISCA (cisplatin vs carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) (abstract 7011). J Clin Oncol 24(18S):366s. 2006.
72. Schiller JH, Harrington A, Belani C, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002.
73. Wakelee H, Schiller J, Gandara D: Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the New Intergroup Trial. Clin Lung Cancer 8:18-21, 2006.